Natalizumab (Tysabri)

Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanis...

Full description

Saved in:
Bibliographic Details
Published in:American journal of neuroradiology : AJNR 2010-10, Vol.31 (9), p.1588-1590
Main Authors: SELEWSKI, D. T, SHAH, G. V, SEGAL, B. M, RAJDEV, P. A, MUKHERJI, S. K
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal, Humanized
Biological and medical sciences
Brain - drug effects
Brain - immunology
Cell Adhesion - drug effects
Cell Adhesion - immunology
Cell Migration Inhibition - drug effects
Cell Migration Inhibition - immunology
Humans
Investigative techniques, diagnostic techniques (general aspects)
Leukocytes - drug effects
Leukocytes - immunology
Medical sciences
Models, Immunological
Multiple Sclerosis - drug therapy
Multiple Sclerosis - immunology
Natalizumab
Nervous system
Pharmacology Vignette
Radiodiagnosis. Nmr imagery. Nmr spectrometry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
ISSN:0195-6108
1936-959X
DOI:10.3174/ajnr.A2226